Loading
companiesCompany
TILT Biotherapeutics
TILT Biotherapeutics is a Finnish biotech founded by Akseli Hemminki whose oncolytic adenovirus TILT-123 produces TNF-alpha and IL-2 in the tumour to help checkpoint inhibitors and TIL therapy work.
Also called: TILT Biotherapeutics Ltd
Overview
TILT Biotherapeutics develops armed oncolytic adenoviruses that replicate in cancer cells and express immune cytokines. TILT-123 (igrelimogene litadenorepvec) carries genes for tumour necrosis factor alpha and interleukin-2, and has been tested with pembrolizumab in platinum-resistant ovarian cancer, with avelumab in solid tumours and with tumour-infiltrating lymphocyte therapy in melanoma. The company has also received funding for phase 2 development in ovarian cancer.
Headquarters
Helsinki, FI
Scorecard
All companies#488of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Founded
2013
Phase 2Oncolytic virus
TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.